The publication in the
The study by Dr.
“This large and well-designed study demonstrates that DPNCheck effectively stages DPN severity. It also contributes to the growing body of research that validates the technical and diagnostic accuracy of DPNCheck and adds to its credibility as a screening and diagnostic tool for DPN and peripheral neuropathy in general,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix.
DPNCheck is an automated, fast, accurate, and quantitative nerve conduction test used to evaluate peripheral neuropathies. It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor peripheral neuropathies. Please visit at www.dpncheck.com
NeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell® 2.0 is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter. For more information, visit NeuroMetrix.com.
SVP and Chief Financial Officer
Source: NeuroMetrix, Inc.